Rapilysin
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Reteplase
- Used in
- Blood, clotting and anaemia
- Made by
- Actavis Group PTC ehf
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
Details
| Made by | Actavis Group PTC ehf |
|---|---|
| Active substance | Reteplase |
| Used in | Blood, clotting and anaemia |
| Classification | B01AD07 · Blood, clotting and anaemia |
| Authorised on | 1996-08-29 |
| Last updated by the regulator | 2026-05-07 |
| EMA product number | EMEA/H/C/000105 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.